Search

Your search keyword '"Sparano, Joseph A"' showing total 23 results
Start Over Author "Sparano, Joseph A" Journal blood
23 results on '"Sparano, Joseph A"'

1. Older Age and Neutrophil-to-Lymphocyte Ratio (NLR) Are Predictors of Illness Severity and COVID-Related Mortality in a Multiethnic Urban Cohort of Hematologic Neoplasms Patients: An Updated Analysis

Author

D'Aiello, Angelica, primary, Zareef, Sumaira, additional, Atalla, Eleftheria, additional, Abbasi, Ahmed, additional, Pradhan, Kith, additional, Lombardo, Amanda, additional, Khatun, Fariha, additional, Mustafa, Jennat, additional, De Castro, Alyssa, additional, Joseph, Felisha, additional, Gillick, Kailyn, additional, Thakkar, Astha, additional, Shapiro, Lauren C, additional, Rahman, Shafia, additional, Cui, Zhu, additional, Gonzalez Lugo, Jesus D, additional, Mienko, Fiona, additional, Rahman, Numa, additional, Lopez, Robert, additional, Ko, Heidi Chwan, additional, Podolski, Amanda, additional, Mehta, Vikas, additional, Goel, Sanjay, additional, Kabarriti, Rafi, additional, Sparano, Joseph, additional, Packer, Stuart, additional, Fernandes, David Lawrence, additional, Castelucci, Enrico, additional, Kushnir, Margarita, additional, Chaitowitz, Mark, additional, Paoluzzi, Luca, additional, Steidl, Ulrich G., additional, Zavras, Phaedon, additional, Cooper, Dennis, additional, Konopleva, Marina, additional, Halmos, Balazs, additional, Mantzaris, Ioannis, additional, Kornblum, Noah, additional, Shastri, Aditi, additional, Bachier-Rodriguez, Lizamarie, additional, Gritsman, Kira, additional, Billett, Henny H., additional, Bartash, Rachel, additional, Puius, Yoram, additional, McCort, Margaret, additional, Braunschweig, Ira, additional, Goldfinger, Mendel, additional, Verma, Amit, additional, and Sica, R. Alejandro, additional

Published
2022
Full Text
View/download PDF

2. Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients

Author

Barta, Stefan K., Xue, Xiaonan, Wang, Dan, Tamari, Roni, Lee, Jeannette Y., Mounier, Nicolas, Kaplan, Lawrence D., Ribera, Josep-Maria, Spina, Michele, Tirelli, Umberto, Weiss, Rudolf, Galicier, Lionel, Boue, Francois, Wilson, Wyndham H., Wyen, Christoph, Oriol, Albert, Navarro, José-Tomás, Dunleavy, Kieron, Little, Richard F., Ratner, Lee, Garcia, Olga, Morgades, Mireia, Remick, Scot C., Noy, Ariela, and Sparano, Joseph A.

Published
2013
Full Text
View/download PDF

3. Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma

Author

for the AIDS Malignancy Consortium, Sparano, Joseph A, Lee, Jeannette Y, Kaplan, Lawrence D, Levine, Alexandra M, Ramos, Juan Carlos, Ambinder, Richard F, Wachsman, William, Aboulafia, David, Noy, Ariela, Henry, David H, Von Roenn, Jamie, Dezube, Bruce J, Remick, Scot C, Shah, Manisha H, Leichman, Lawrence, Ratner, Lee, Cesarman, Ethel, Chadburn, Amy, and Mitsuyasu, Ronald

Published
2010
Full Text
View/download PDF

4. Older Age and Increased Neutrophil-to-Lymphocyte Ratio (NLR) Are Predictors of Mortality in a Multiethnic Urban Cohort of Hematologic Neoplasms and COVID-19 Patients

Author

D'Aiello, Angelica, primary, Zareef, Sumaira, additional, Pradhan, Kith, additional, Lombardo, Amanda, additional, Khatun, Fariha, additional, Mustafa, Jennat, additional, De Castro, Alyssa, additional, Joseph, Felisha, additional, Gillick, Kailyn, additional, Naik, Anjali, additional, Thakkar, Astha, additional, Shapiro, Lauren C, additional, Rahman, Shafia, additional, Cui, Zhu, additional, Gonzalez Lugo, Jesus D, additional, Mienko, Fiona, additional, Rahman, Numa Tarnima, additional, Lopez, Robert, additional, Ko, Heidi Chwan, additional, Podolski, Amanda, additional, Mehta, Vikas, additional, Goel, Sanjay, additional, Kabarriti, Rafi, additional, Sparano, Joseph, additional, Packer, Stuart, additional, Fernandes, David Lawrence, additional, Castelucci, Enrico, additional, Kushnir, Margarita, additional, Chaitowitz, Mark, additional, Paoluzzi, Luca, additional, Steidl, Ulrich G., additional, Zavras, Phaedon, additional, Mantzaris, Ioannis, additional, Kornblum, Noah, additional, Shastri, Aditi, additional, Bachier-Rodriguez, Lizamarie, additional, Gritsman, Kira, additional, Billett, Henny H., additional, Bartash, Rachel, additional, Puius, Yoram, additional, Mccort, Margaret, additional, Braunschweig, Ira, additional, Goldfinger, Mendel, additional, Verma, Amit, additional, and Sica, R. Alejandro, additional

Published
2020
Full Text
View/download PDF

5. Impact of Myc in HIV-associated non-Hodgkin lymphomas treated with EPOCH and outcomes with vorinostat (AMC-075 trial)

Author

Ramos, Juan C., primary, Sparano, Joseph A., additional, Chadburn, Amy, additional, Reid, Erin G., additional, Ambinder, Richard F., additional, Siegel, Eric R., additional, Moore, Page C., additional, Rubinstein, Paul G., additional, Durand, Christine M., additional, Cesarman, Ethel, additional, Aboulafia, David, additional, Baiocchi, Robert, additional, Ratner, Lee, additional, Kaplan, Lawrence, additional, Capoferri, Adam A., additional, Lee, Jeannette Y., additional, Mitsuyasu, Ronald, additional, and Noy, Ariela, additional

Published
2020
Full Text
View/download PDF

6. Response-Adapted Therapy with Infusional EPOCH Chemotherapy Plus Rituximab in HIV-Associated, B-Cell Non-Hodgkin's Lymphoma

Author

Ramos, Juan Carlos, primary, Ambinder, Richard F., additional, Sparano, Joseph, additional, Lee, Jeannette Y, additional, Kaplan, Lawrence D, additional, Wachsman, William, additional, Aboulafia, David M., additional, Noy, Ariela, additional, Ratner, Lee, additional, Henry, David H., additional, Chadburn, Amy, additional, Cesarman, Ethel, additional, and Mitsuyasu, Ronald T., additional

Published
2019
Full Text
View/download PDF

7. A Randomized Trial of EPOCH-Based Chemotherapy with Vorinostat for Highly Aggressive HIV-Associated Lymphomas: Updated Results Evaluating Impact of Diagnosis-to-Treatment Interval (DTI) and Pre-Protocol Systemic Therapy on Outcomes

Author

Ramos, Juan Carlos, primary, Sparano, Joseph, additional, Moore, Page C., additional, Siegel, Eric, additional, Lee, Jeannette Y, additional, Reid, Erin G., additional, Ambinder, Richard F., additional, Chadburn, Amy, additional, Rubinstein, Paul G., additional, Durand, Christine, additional, Cesarman, Ethel, additional, Ratner, Lee, additional, Baiocchi, Robert A, additional, Aboulafia, David M., additional, Kaplan, Lawrence D, additional, Capoferri, Adam, additional, Mitsuyasu, Ronald T., additional, and Noy, Ariela, additional

Published
2019
Full Text
View/download PDF

9. Final Results of a CTEP Sponsored Phase I Study of Alistertib in Combination with Bortezomib and Rituximab in Relapsed and Refractory Mantle Cell and Low Grade Non-Hodgkin Lymphoma

Author

Barta, Stefan Klaus, primary, Kornblum, Noah, additional, Raphael, Bruce G., additional, Hymes, Kenneth B., additional, Grossbard, Michael L., additional, Moskovits, Tibor, additional, Handorf, Elizabeth, additional, Sparano, Joseph, additional, Piekarz, Richard, additional, and Diefenbach, Catherine, additional

Published
2018
Full Text
View/download PDF

11. AMC-053: Pilot Study of an Oncolytic Viral Strategy Using Bortezomib with ICE +/- Rituximab for Relapsed/Refractory HIV+ Lymphomas

Author

Reid, Erin Gourley, primary, Looney, David, additional, Maldarelli, Frank, additional, Noy, Ariela, additional, Henry, David H., additional, Aboulafia, David M., additional, Ramos, Juan Carlos, additional, Sparano, Joseph, additional, Ambinder, Richard F., additional, Lee, Jeannette, additional, Mitsuyasu, Ronald T., additional, and Wachsman, William, additional

Published
2016
Full Text
View/download PDF

13. A Phase II Trial Of Epigenetic Modulators Vorinostat In Combination With Azacitidine (azaC) In Patients With The Myelodysplastic Syndrome (MDS): Initial Results Of Study 6898 Of The New York Cancer Consortium

Author

Silverman, Lewis R., primary, Verma, Amit, additional, Odchimar-Reissig, Rosalie, additional, Feldman, Eric J., additional, Navada, Shyamala C., additional, Demakos, Erin P, additional, Baer, Maria R., additional, Najfeld, Vesna, additional, Sparano, Joseph A, additional, and Piekarz, Richard, additional

Published
2013
Full Text
View/download PDF

14. ARL-IPI - A New Prognostic Score for AIDS-Related Lymphomas in the Rituximab Era

Author

Barta, Stefan K, primary, Xue, Xiaonan, additional, Wang, Dan, additional, Lee, Jeannette Y, additional, Kaplan, Lawrence D., additional, Ribera, Josep-Maria, additional, Oriol, Albert, additional, Garcia, Olga, additional, Morgades, Mireia, additional, Spina, Michele, additional, Tirelli, Umberto, additional, Boue, Francois, additional, Wilson, Wyndham H., additional, Wyen, Christoph, additional, Dunleavy, Kieron, additional, and Sparano, Joseph A, additional

Published
2012
Full Text
View/download PDF

15. A Pooled Analysis of 1,546 Patients with HIV-Associated Lymphoma: Assessment of Lymphoma-, HIV-, and Treatment-Specific Factors On Clinical Outcomes

Author

Barta, Stefan K, primary, Xue, Xiaonan, additional, Wang, Dan, additional, Tamari, Roni, additional, Lee, Jeannette Y, additional, Mounier, Nicolas, additional, Kaplan, Lawrence D., additional, Ribera, Josep-Maria, additional, Spina, Michele, additional, Tirelli, Umberto, additional, Weiss, Rudolf, additional, Galicier, Lionel, additional, Boue, Francois, additional, Wilson, Wyndham H., additional, Wyen, Christoph, additional, Oriol, Albert, additional, Navarro, Jose-Tomas, additional, Dunleavy, Kieron, additional, Little, Richard F, additional, Ratner, Lee, additional, Garcia, Olga, additional, Morgades, Mireia, additional, Oksenhendler, Eric, additional, Remick, Scot, additional, and Sparano, Joseph A, additional

Published
2012
Full Text
View/download PDF

20. Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma

Author

Sparano, Joseph A., Lee, Jeannette Y., Kaplan, Lawrence D., Levine, Alexandra M., Ramos, Juan Carlos, Ambinder, Richard F., Wachsman, William, Aboulafia, David, Noy, Ariela, Henry, David H., Von Roenn, Jamie, Dezube, Bruce J., Remick, Scot C., Shah, Manisha H., Leichman, Lawrence, Ratner, Lee, Cesarman, Ethel, Chadburn, Amy, and Mitsuyasu, Ronald

Abstract

Rituximab plus intravenous bolus chemotherapy is a standard treatment for immunocompetent patients with B-cell non-Hodgkin lymphoma (NHL). Some studies have suggested that rituximab is associated with excessive toxicity in HIVassociated NHL, and that infusional chemotherapy may be more effective. We performed a randomized phase 2 trial of rituximab (375 mg/m2) given either concurrently before each infusional etoposide, vincristine, doxorubicin, cyclophosphamide, and prednisone (EPOCH) chemotherapy cycle or sequentially (weekly for 6 weeks) after completion of all chemotherapy in HIV-associated NHL. EPOCH consisted of a 96-hour intravenous infusion of etoposide, doxorubicin, and vincristine plus oral prednisone followed by intravenous bolus cyclophosphamide given every 21 days for 4 to 6 cycles. In the concurrent arm, 35 of 48 evaluable patients (73%; 95% confidence interval, 58%-85%) had a complete response. In the sequential arm, 29 of 53 evaluable patients (55%; 95% confidence interval, 41%-68%) had a complete response. The primary efficacy endpoint was met for the concurrent arm only. Toxicity was comparable in the 2 arms, although patients with a baseline CD4 count less than 50/μL had a high infectious death rate in the concurrent arm. We conclude that concurrent rituximab plus infusional EPOCH is an effective regimen for HIV-associated lymphoma. This study is registered at http://clinicaltrials.gov as NCT00049036.

Published
2010
Full Text
View/download PDF

21. Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma

Author

Consortium, for the AIDS Malignancy, Sparano, Joseph A, Lee, Jeannette Y, Kaplan, Lawrence D, Levine, Alexandra M, Ramos, Juan Carlos, Ambinder, Richard F, Wachsman, William, Aboulafia, David, Noy, Ariela, Henry, David H, Von Roenn, Jamie, Dezube, Bruce J, Remick, Scot C, Shah, Manisha H, Leichman, Lawrence, Ratner, Lee, Cesarman, Ethel, Chadburn, Amy, and Mitsuyasu, Ronald

Abstract

Rituximab plus intravenous bolus chemotherapy is a standard treatment for immunocompetent patients with B-cell non-Hodgkin lymphoma (NHL). Some studies have suggested that rituximab is associated with excessive toxicity in HIVassociated NHL, and that infusional chemotherapy may be more effective. We performed a randomized phase 2 trial of rituximab (375 mg/m2) given either concurrently before each infusional etoposide, vincristine, doxorubicin, cyclophosphamide, and prednisone (EPOCH) chemotherapy cycle or sequentially (weekly for 6 weeks) after completion of all chemotherapy in HIV-associated NHL. EPOCH consisted of a 96-hour intravenous infusion of etoposide, doxorubicin, and vincristine plus oral prednisone followed by intravenous bolus cyclophosphamide given every 21 days for 4 to 6 cycles. In the concurrent arm, 35 of 48 evaluable patients (73%; 95% confidence interval, 58%-85%) had a complete response. In the sequential arm, 29 of 53 evaluable patients (55%; 95% confidence interval, 41%-68%) had a complete response. The primary efficacy endpoint was met for the concurrent arm only. Toxicity was comparable in the 2 arms, although patients with a baseline CD4 count less than 50/μL had a high infectious death rate in the concurrent arm. We conclude that concurrent rituximab plus infusional EPOCH is an effective regimen for HIV-associated lymphoma. This study is registered at http://clinicaltrials.govas NCT00049036.

Published
2010
Full Text
View/download PDF

22. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010

Author

Kaplan, Lawrence D., Lee, Jeannette Y., Ambinder, Richard F., Sparano, Joseph A., Cesarman, Ethel, Chadburn, Amy, Levine, Alexandra M., and Scadden, David T.

Abstract

The addition of rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy results in significant improvement in clinical outcome for individuals with non–HIV-associated aggressive B-cell lymphoma. To assess the potential risks and benefits of the addition of rituximab to CHOP for HIV-associated non-Hodgkin lymphoma (HIV-NHL) 150 patients receiving CHOP for HIV-NHL were randomized (2:1) to receive 375 mg/m2 rituximab with each chemotherapy cycle (n = 99) or no immunotherapy (n = 50) in a multicenter phase 3 trial. The complete response rate (CR + CRu) was 57.6% for R-CHOP and 47% for CHOP (P = .147). With a median follow-up of 137 weeks, time to progression, progression-free survival, and overall survival times were 125, 45, and 139 weeks, respectively, for R-CHOP and 85, 38, and 110 weeks, respectively, for CHOP (P = not significant, all comparisons). Treatment-related infectious deaths occurred in 14% of patients receiving R-CHOP compared with 2% in the chemotherapy-alone group (P = .035). Of these deaths, 60% occurred in patients with CD4 counts less than 50/mm3. Progression-free survival was significantly influenced by CD4+ count (P < .001) and International Prognostic Index score (P = .022), but not bcl-2 status. The addition of rituximab to CHOP in patients with HIV-NHL may be associated with improved tumor responses. However, these benefits may be offset by an increase in infectious deaths, particularly in those individuals with CD4+ lymphocyte counts less than 50/mm3.

Published
2005
Full Text
View/download PDF

23. Infusional Cyclophosphamide, Doxorubicin, and Etoposide in Human Immunodeficiency Virus– and Human T-Cell Leukemia Virus Type I–Related Non-Hodgkin’s Lymphoma: A Highly Active Regimen

Author

Sparano, Joseph A., Wiernik, Peter H., Strack, Margery, Leaf, Andrea, Becker, Norwin, and Valentine, Edward S.

Abstract

Fourteen patients with poor-prognosis intermediate- to high-grade non-Hodgkin’s lymphoma (NHL) associated with human immunodeficiency virus (HIV) infection (12 patients) or human T-cell leukemia virus type I (HTLV-I) infection (two patients) received cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2, and etoposide 240 mg/m2administered as a continuous intravenous (IV) infusion over 4 days (infusional CDE); treatment was repeated every 28 or more days for up to six cycles. All HIV-positive patients had at least one poor prognostic feature, which included either extranodal disease (10 patients), Karnofsky performance status less than 70% (six patients), a CD4 count less than 100/µL (six patients), or a prior history of acquired immunodeficiency syndrome (AIDS; one patient). Both HTLV-I–positive patients had an elevated serum lactate dehydrogenase (LDH) level, a poor prognostic feature in that setting. Complete response (CR) occurred in 10 patients (71%; 95% confidence interval, 48% to 95%) and partial response (PR) occurred in three patients (21%), yielding an overall objective response rate of approximately 93%. The estimated Kaplan-Meier median survival was 17.4 months; seven of 12 HIV-positive patients are alive and disease-free with a median follow-up of 15 months (range, 7 to 24 months). Hospitalization was required after 19% of treatment cycles due to fever associated with granulocytopenia. Documented or suspected opportunistic infection occurred in five patients (36%), bacteremia occurred in three patients (21%), and candidemia occurred in one patient (7%). There was one treatment-related death attributable to disseminated aspergillosis. This pilot study suggests that infusional CDE may be a highly active regimen capable of producing durable remissions in a high proportion of patients with HIV-related NHL. Further study is required to confirm this observation.

Published
1993
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results